These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 1600360)

  • 1. Selegiline--an overview of its role in the treatment of Parkinson's disease.
    Wessel K; Szelenyi I
    Clin Investig; 1992 May; 70(5):459-62. PubMed ID: 1600360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selegiline in the treatment of Parkinson's disease.
    Heinonen EH; Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():103-11. PubMed ID: 2515715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1991; 136():95-8. PubMed ID: 1801545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.
    Bryson HM; Milne RJ; Chrisp P
    Pharmacoeconomics; 1992 Aug; 2(2):118-36. PubMed ID: 10146952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline and the prophylaxis of Parkinson's disease.
    Sandler M; Willoughby J; Glover V; Gibb C
    J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.
    Chrisp P; Mammen GJ; Sorkin EM
    Drugs Aging; 1991 May; 1(3):228-48. PubMed ID: 1794016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
    Gerlach M; Desser H; Youdim MB; Riederer P
    J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of the pharmacology of selegiline.
    Heinonen EH; Lammintausta R
    Acta Neurol Scand Suppl; 1991; 136():44-59. PubMed ID: 1686954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zydis selegiline in the management of Parkinson's disease.
    Poston KL; Waters C
    Expert Opin Pharmacother; 2007 Oct; 8(15):2615-24. PubMed ID: 17931095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
    Olanow CW
    J Neural Transm Suppl; 1996; 48():75-84. PubMed ID: 8988463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selegiline can mediate neuronal rescue rather than neuronal protection.
    Tatton WG
    Mov Disord; 1993; 8 Suppl 1():S20-30. PubMed ID: 8302304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective actions of selegiline.
    Ebadi M; Sharma S; Shavali S; El Refaey H
    J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.